Search Results for: f

ACTUATE THERAPEUTICS SUBMITS IND APPLICATION FOR TREATMENT OF REFRACTORY CANCERS

CHICAGO, IL and FORT WORTH, TX, January 15, 2018 – Actuate Therapeutics, Inc., a clinical stage biopharmaceutical company, today announced that it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) to begin clinical study of 9-ING-41, Actuate’s lead agent – a proprietary GSK-3β inhibitor. This initial IND […]

ACTUATE THERAPEUTICS SUBMITS IND APPLICATION FOR TREATMENT OF REFRACTORY CANCERS Read More »

ACTUATE THERAPEUTICS RECEIVES RARE PEDIATRIC DISEASE DESIGNATION FOR 9-ING-41 FOR TREATMENT OF NEUROBLASTOMA

CHICAGO, IL and FORT WORTH, TX, October 26, 2017 – Actuate Therapeutics, Inc., a clinical stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to 9-ING-41, Actuate’s lead clinical development candidate, for the treatment of neuroblastoma. The Rare Pediatric Disease Designation of 9-ING for the

ACTUATE THERAPEUTICS RECEIVES RARE PEDIATRIC DISEASE DESIGNATION FOR 9-ING-41 FOR TREATMENT OF NEUROBLASTOMA Read More »

DR. FRANCIS GILES JOINS ACTUATE THERAPEUTICS AS CHIEF MEDICAL OFFICER

CHICAGO, IL and FORT WORTH, TX, March 1, 2017 – Actuate Therapeutics, Inc., a Chicago-based biopharmaceutical company, today announced the appointment of Francis J. Giles, MB, MD, FRCPI, FRCPath to the newly created position of Chief Medical Officer (CMO). Dr. Giles will be responsible for advancing Actuate’s research and development initiatives, leading the clinical programs,

DR. FRANCIS GILES JOINS ACTUATE THERAPEUTICS AS CHIEF MEDICAL OFFICER Read More »